Company / EPS (Diluted)
Krystal Biotech, Inc. EPS (Diluted) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$0.39
FY2025
5-year range
-$5.49 / $0.39
FY2021-FY2025
Trend
+107.1%
vs FY2024
Sector context
#39 of 204
Health Care
What the data says
Krystal Biotech, Inc.'s eps (diluted) of $0.39 is higher than 81% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 6 years, ranging from $-5.49 in FY2024 to $0.39 in FY2025.
Based on SEC 10-K filings.
0.39 in FY2025. Top quartile in the Health Care sector.
Improved from $-3.13 to $0.39 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 19% in Health CareTop 19% of 204This company $0.39 Sector average -$0.89
▼
+144.0% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 107.1% year-over-year.
- Ranks #39 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 5.66 (safe zone, above 2.9 threshold)
- Strong profit margin: 30.7%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $0.39 | +107.1% |
| FY2024 | -$5.49 | -75.4% |
| FY2023 | -$3.13 | +43.0% |
| FY2022 | -$5.49 | -75.4% |
| FY2021 | -$3.13 | -83.0% |
| FY2020 | -$1.71 | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026